A Clinical Study Investigating the Efficacy, Tolerability, and Safety of Continuous Subcutaneous ND0612 Infusion Given as Adjunct Treatment to Oral Levodopa in Patients With Parkinson's Disease With Motor Fluctuations
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02782481 |
Recruitment Status :
Withdrawn
(Decision to change the study design)
First Posted : May 25, 2016
Last Update Posted : December 10, 2019
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Parkinson's Disease | Drug: ND0612 Drug: Placebo | Phase 3 |
This phase III randomized, double-blind, placebo controlled, parallel group clinical study will be conducted in 150 subjects with idiopathic PD who are experiencing motor complications despite optimized anti-PD therapy.
The study will investigate the efficacy, safety and tolerability of continuous SC infusion (16 weeks) of ND0612 compared with placebo infusion. The treatment period will be comprised of a 4-week adjustment period during which time the ND0612 infusion dose will remain constant and the oral LD/DDI dose can be decreased or increased back up to the Baseline levels. All other anti-PD treatments must remain constant. During the maintenance period (Weeks 5 to 16) all anti-PD medication including the ND0612/placebo should remain constant.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 0 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | A Multicenter, Randomized, Double-blind, Placebo Controlled, Parallel Group Clinical Study Investigating the Efficacy, Tolerability, and Safety of Continuous Subcutaneous ND0612 Infusion Given as Adjunct Treatment to Oral Levodopa in Patients With Parkinson's Disease With Motor Fluctuations |
Actual Study Start Date : | August 2016 |
Actual Primary Completion Date : | October 15, 2018 |
Actual Study Completion Date : | October 15, 2018 |

Arm | Intervention/treatment |
---|---|
Experimental: ND0612 High dose (Levodopa/Carbidopa solution)
High dose ND0612 SC infusion over 24 h
|
Drug: ND0612
Other Name: Levodopa/Carbidopa solution |
Experimental: ND0612 Low dose (Levodopa/Carbidopa solution)
Low dose ND0612 SC infusion over 24 h
|
Drug: ND0612
Other Name: Levodopa/Carbidopa solution |
Placebo Comparator: Placebo
Placebo SC infusion over 24 h
|
Drug: Placebo
Other Name: Placebo solution |
- The change from Baseline to Week 16 in the mean percentage of "OFF" time during waking hours, based on patient's home diary assessments [ Time Frame: baseline to week 16 ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 30 Years to 80 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Key Inclusion Criteria:
- Male and female PD subjects of any race aged 30-80 years
- PD diagnosis consistent with the UK Brain Bank Criteria.
- Modified Hoehn & Yahr scale in "ON" state ≤3
- Subjects must experience motor fluctuations and experience an average of at least 2 hours daily in the "OFF" state
- Taking at least 4 doses/day of IR LD/DDI (or at least 3 doses/day of Rytary) and taking, or having taken therapeutic doses of at least 2 other classes of anti-PD medications.
- Subjects must be on stable doses of all their anti-PD medications for at least 28 days before Baseline (Day 1).
- Subject and/or study partner must demonstrate ability to keep accurate diary entries of PD symptoms ("ON-OFF" diaries) with at least 75% concordance with the study rater by the end of the diary training session at the end of the screening period.
- Mini Mental State Examination (MMSE) score >26.
- Female subjects must be surgically sterile (hysterectomy, bilateral oophorectomy, or tubal ligation), postmenopausal (defined as cessation of menses for at least 1 year), or willing to practice a highly effective method of contraception.
Key Exclusion Criteria:
- Atypical or secondary parkinsonism.
- Psychosis or hallucinations in past 6 months.
- Subjects with a clinically significant or unstable medical, surgical, psychiatric condition or laboratory abnormalities which, in the opinion of the Investigator or the EAC, represents a safety risk, makes the subject unsuitable for study entry or potentially unable to complete all aspects of the study.
- Clinically significant ECG abnormalities.
- Renal or liver dysfunction that may alter drug metabolism including Screening visit serum levels of creatinine >1.3 mg/dL, aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >2x upper limit of normal (ULN), total bilirubin >2.5 mg/dL.
- Positive serum serology for Hepatitits B Virus (HBV), Hepatitits C Virus (HCV) or Human Immunodeficiency Virus (HIV) at the Screening visit
- Any malignancy in the 5 years prior to randomization excluding basal cell carcinoma of the skin or cervical carcinoma in situ that have been successfully treated
- Use of prohibited medications as per protocol
- Subjects who have previously undergone treatment for PD with a neurosurgical intervention (e.g., pallidotomy, thalamotomy, transplantation, deep brain stimulation procedures), Duodopa/Duopa, or continuous dopaminergic or apomorphine infusion.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02782481
Israel | |
Haddasah Ein Kerem Medical center | |
Jerusalem, Israel |
Responsible Party: | NeuroDerm Ltd. |
ClinicalTrials.gov Identifier: | NCT02782481 |
Other Study ID Numbers: |
ND0612L-007 |
First Posted: | May 25, 2016 Key Record Dates |
Last Update Posted: | December 10, 2019 |
Last Verified: | December 2019 |
Parkinson Disease Parkinsonian Disorders Basal Ganglia Diseases Brain Diseases Central Nervous System Diseases Nervous System Diseases Movement Disorders Synucleinopathies Neurodegenerative Diseases Levodopa |
Carbidopa Pharmaceutical Solutions Antiparkinson Agents Anti-Dyskinesia Agents Dopamine Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Aromatic Amino Acid Decarboxylase Inhibitors Enzyme Inhibitors |